Recombinant vesicular stomatitis virus vector vaccines for WHO blueprint priority pathogens

Area of Science:

• Virology
• Vaccinology
• Epidemiology

Background:

• The 2013-2016 Ebola virus (EBOV) outbreak highlighted the urgent need for rapid vaccine development against high-threat pathogens.
• The World Health Organization (WHO) identifies priority pathogens for research and development (R&D) to prepare for future epidemics.
• Effective vaccine platforms are crucial for timely responses to emerging infectious disease threats.

Discussion:

• Vesicular stomatitis virus (VSV) has a proven track record as a vaccine vector for over a decade.
• Recent clinical trials of the VSV-EBOV vaccine candidate against EBOV disease provide valuable clinical data.
• VSV demonstrates potential as an ideal vaccine vector for outbreak pathogens.

Key Insights:

• Clinical data from VSV-EBOV trials confirm VSV's safety and immunogenicity.
• Animal studies investigating VSV-based vaccines for WHO Blueprint pathogens show promising results.
• VSV vector technology offers a flexible platform for developing vaccines against diverse infectious agents.

Outlook:

• Further research and development of VSV-based vaccines are essential for pandemic preparedness.
• Continued characterization of VSV as a vaccine vector will accelerate R&D for priority pathogens.
• The VSV platform holds significant promise for combating future epidemic threats.